Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Journal of Pharmacology and Experimental Therapeutics|May 23, 2002
Characterization of neuromedin U effects in canine smooth muscleTimothy D Westfall, Gerald P McCafferty, Mark Pullen, et al.The Journal of Pharmacology and Experimental Therapeutics|July 14, 2007
GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dogAlexandra Hicks, Gerald P McCafferty, Erin Riedel, et al.The Journal of Pharmacology and Experimental Therapeutics|June 27, 2009
Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular diseaseRobert N Willette, Marianne E Eybye, Alan R Olzinski, et al.American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|March 31, 2007
Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the ratGerald P McCafferty, Mark A Pullen, Charlene Wu, et al.Journal of Medicinal Chemistry|January 14, 2012
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potencyAlan D Borthwick, John Liddle, Dave E Davies, et al.The Journal of Pharmacology and Experimental Therapeutics|May 24, 2008
N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part IKevin S Thorneloe, Anthony C Sulpizio, Zuojun Lin, et al.Bioorganic & Medicinal Chemistry Letters|November 23, 2007
The discovery of GSK221149A: a potent and selective oxytocin antagonistJohn Liddle, Michael J Allen, Alan D Borthwick, et al.Pageof 2